InvestorsHub Logo
Followers 231
Posts 14718
Boards Moderated 1
Alias Born 03/29/2014

Re: BWIS post# 209929

Thursday, 01/24/2019 6:51:13 PM

Thursday, January 24, 2019 6:51:13 PM

Post# of 704062
The journal specifically states this...

The study’s primary endpoint is PFS, and the secondary endpoint is OS. PFS has not yet been evaluated for this publication and will be the subject of later analyses to allow for central, multi-factorial assessment by an expert panel, using criteria currently emerging as appropriate for immune therapy in this patient population where progression can be complex to determine and pseudo-progression is a known confounding phenomenon.



https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News